These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33489708)

  • 21. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
    Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
    JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.
    Kimura H; Sone T; Araya T; Murata A; Yamamura K; Ohkura N; Hara J; Abo M; Kasahara K
    Transl Lung Cancer Res; 2021 Mar; 10(3):1576-1581. PubMed ID: 33889531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
    Li D; He C; Xia Y; Du Y; Zhang J
    J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
    Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
    In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vision loss with pembrolizumab treatment: A report of two cases.
    Telfah M; Whittaker TJ; C Doolittle G
    J Oncol Pharm Pract; 2019 Sep; 25(6):1540-1546. PubMed ID: 30997872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
    Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
    BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Case Report of Pembrolizumab-Induced Allergic Hepatitis.
    Nakatani S; Fukushima M; Akahani S
    Cureus; 2024 Jul; 16(7):e64703. PubMed ID: 39156358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study.
    Egami S; Kawazoe H; Hashimoto H; Uozumi R; Arami T; Sakiyama N; Ohe Y; Nakada H; Aomori T; Ikemura S; Fukunaga K; Yamaguchi M; Nakamura T
    J Cancer; 2021; 12(7):2105-2112. PubMed ID: 33754009
    [No Abstract]   [Full Text] [Related]  

  • 30. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
    Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review.
    Tan Q; Liu L; Huang Y; Dong X; Chen L
    Front Oncol; 2022; 12():973421. PubMed ID: 36505877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer.
    Machida M; Yamazaki C; Kouda N; Hanai Y; Sato H; Konda A; Yamagata Y; Itho T; Aisaka H
    J Pharm Health Care Sci; 2022 Dec; 8(1):29. PubMed ID: 36464708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
    Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
    J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced "Eosinophilic Fasciitis-Like" Case and a Review of the Literature.
    Salamaliki C; Solomou EE; Liossis SC
    Rheumatol Ther; 2020 Dec; 7(4):1045-1052. PubMed ID: 33067734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.
    Niki M; Nakaya A; Kurata T; Nakahama K; Yoshioka H; Kaneda T; Kibata K; Ogata M; Nomura S
    Mol Clin Oncol; 2019 Feb; 10(2):267-269. PubMed ID: 30680206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary Raynaud's Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.
    Lee YJ; Park K
    Drug Saf Case Rep; 2018 Feb; 5(1):7. PubMed ID: 29417244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection.
    Zhou C; Klionsky Y; Treasure ME; Bruno DS
    Case Rep Oncol; 2019; 12(1):164-170. PubMed ID: 31043955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report.
    Saito Y; Takekuma Y; Asahina H; Hisada R; Sugawara M
    Case Rep Oncol Med; 2024; 2024():1566299. PubMed ID: 38361964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.